Drug Pipeline

PD-L1 t-haNK Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
3
Recruiting
3
Top Sponsors
3
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-02 NCT04847466
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803…		 Trial completed
2026-06-02 NCT04847466
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803…		 date change Primary completion moved earlier: 2027-01-31 -> 2025-12-22
2026-06-02 NCT04847466
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803…		 date change Completion moved earlier: 2027-12-31 -> 2026-01-06
Active Studies by Phase
Phase 2
3
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT06061809 N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma Glioblastoma Recruiting
NCT02727803 Personalized NK Cell Therapy in CBT Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recruiting
NCT06239220 PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC Head and Neck Cancer Recruiting
Sponsors Running PD-L1 t-haNK Trials
M.D. Anderson Cancer Center (1) ImmunityBio, Inc. (1) Glenn J. Hanna (1)
Disease Areas
Leukemia (1) Acute Myeloid Leukemia (AML) (1) Acute Lymphoblastic Leukemia (ALL) (1) Multiple Myeloma (1) Non-Hodgkin Lymphoma (1) Hodgkin Lymphoma (1) Myelodysplastic Syndromes (MDS) (1) Myelofibrosis (1) Glioblastoma (1) Head & Neck Cancer (1)
Get alerts when PD-L1 t-haNK trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free